Amanda Gerberich, PharmD, BCPS
Clinical Assistant Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
Approximately 23,000 hematopoietic cell transplants (HCTs) are performed in the United States annually for the treatment of malignant and nonmalignant diseases.1 The most common malignant indications for HCT include multiple myeloma, non-Hodgkin lymphoma (NHL), and acute myelogenous leukemia (AML).1 Nonmalignant indications include diseases characterized by an
JUNE 10, 2020